PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16135024

A semiparametric mixture model for analyzing clustered competing risks data.

Malay Naskar·Kalyan Das·Joseph G Ibrahim
View original source ↗Export metadata ↓

Abstract

A very general class of multivariate life distributions is considered for analyzing failure time clustered data that are subject to censoring and multiple modes of failure. Conditional on cluster-specific quantities, the joint distribution of the failure time and event indicator can be expressed as a mixture of the distribution of time to failure due to a certain type (or specific cause), and the failure type distribution. We assume here the marginal probabilities of various failure types are logistic functions of some covariates. The cluster-specific quantities are subject to some unknown distribution that causes frailty. The unknown frailty distribution is modeled nonparametrically using a Dirichlet process. In such a semiparametric setup, a hybrid method of estimation is proposed based on the i.i.d. Weighted Chinese Restaurant algorithm that helps us generate observations from the predictive distribution of the frailty. The Monte Carlo ECM algorithm plays a vital role for obtaining the estimates of the parameters that assess the extent of the effects of the causal factors for failures of a certain type. A simulation study is conducted to study the consistency of our methodology. The proposed methodology is used to analyze a real data set on HIV infection of a cohort of female prostitutes in Senegal.

Explore related subjects

AIDS VaccinesAlgorithmsCluster AnalysisCohort StudiesComputer SimulationFemaleHIV InfectionsHIV-1HIV-2HumansModels, StatisticalMonte Carlo MethodRiskSenegalSex WorkSurvival AnalysisJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Malay Naskar, Kalyan Das, Joseph G Ibrahim. 2005. A semiparametric mixture model for analyzing clustered competing risks data.. https://doi.org/10.1111/j.1541-0420.2005.00341.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2025

Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies.

Antibodies belonging to the VRC01-class display broad and potent neutralizing activities and have been isolated from several people living with HIV (PLWH). A member of that class, monoclonal antibody VRC01, was shown to reduce HIV-acquisition in two phase 2b efficacy trials. VRC01-class antibodies are therefore expected to be one component of an effective HIV-1 vaccine elicited response. In contrast to the VRC01-class antibodies that are highly mutated, their unmutated forms do not engage HIV-1 envelope (Env) and do not display neutralizing activities. Hence, specifically modified Env-derived proteins have been designed to engage the unmutated forms of VRC01-class antibodies, and to activate the corresponding naïve B cells. Selected heterologous Env must then be used as boost immunogens to guide the proper maturation of these elicited VRC01-class antibodies. Here we examined whether and how the valency of the prime and boost immunogens influences VRC01-class antibody-maturation. Our findings indicate that, indeed the valency of the immunogen affects the maturation of elicited antibody responses by preferentially selecting VRC01-like antibodies that have accumulated somatic mutations present in broadly neutralizing VRC01-class antibodies isolated from PLWH. As a result, antibodies isolated from animals immunized with the higher valency immunogens display broader Env cross-binding properties and improved neutralizing potentials than those isolated from animals immunized with the lower valency immunogens. Our results are relevant to current and upcoming phase 1 clinical trials that evaluate the ability of novel immunogens aiming to elicit cross-reactive VRC01-class antibody responses.

AIDS Vaccines↗
PubMed2015

New approaches to HIV vaccine development.

Development of a safe and effective vaccine for HIV is a major global priority. However, to date, efforts to design an HIV vaccine with methods used for development of other successful viral vaccines have not succeeded due to HIV diversity, HIV integration into the host genome, and ability of HIV to consistently evade anti-viral immune responses. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs), in discovery of mechanisms of bnAb induction, and in discovery of atypical mechanisms of CD8T cell killing of HIV-infected cells, have opened new avenues for strategies for HIV vaccine design.

AIDS Vaccines↗
PubMed2006

HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment.

BACKGROUND: Underrepresentation of ethnic minority communities limits the generalizability of HIV vaccine trial results. We explored perceived barriers and motivators regarding HIV vaccine trial participation among low-socioeconomic ethnic minority respondents at risk for HIV. METHODS: Six focus group interviews were conducted using a semistructured interview guide. Participants (N = 58, mean age = 36 years, 37% female, and 56% Latino/a and 35% African American) were recruited using venue-based sampling in Los Angeles. Data were analyzed using narrative thematic analysis and Ethnograph qualitative software. RESULTS: Perceived barriers to HIV vaccine trial participation, in rank order, were (1) vaccine-induced HIV infection, (2) physical side effects, (3) uncertainty about vaccine efficacy, (4) uncertainty about other vaccine characteristics, (5) mistrust, (6) low perceived HIV risk, (7) study demands, (8) stigma, and (9) vaccine-induced HIV seropositivity. Motivators were (1) protection against HIV infection, (2) free insurance and/or medical care, (3) altruism, and (4) monetary incentives. CONCLUSIONS: Population-specific HIV vaccine trial recruitment and implementation strategies should address trial risks from a family perspective, cultural gender norms, mistrust, low perceived HIV risk, the importance of African-American and Latino/a community participation in HIV vaccine trials, and misconceptions about gaining protection against HIV infection. Increasing the cultural relevance of trial recruitment and implementation should facilitate the participation of Latinos/as and African Americans in HIV vaccine trials.

AIDS Vaccines↗